Loading…
Lixte Biotechnology Holdings, Inc. is projected to rise to $7.40 by 2027, a +15% move from its current price of $6.42. LIXT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $6.06 | $6.43 | $6.81 | +0.09% |
| May 30 | $5.92 | $6.43 | $6.98 | +0.18% |
| May 31 | $5.82 | $6.44 | $7.12 | +0.27% |
| Jun 1 | $5.74 | $6.44 | $7.24 | +0.36% |
| Jun 2 | $5.66 | $6.45 | $7.34 | +0.45% |
| Jun 3 | $5.60 | $6.45 | $7.44 | +0.54% |
| Jun 4 | $5.54 | $6.46 | $7.53 | +0.63% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.54 | $6.46 | $7.53 | +0.63% |
| Week 2 | $5.23 | $6.50 | $8.08 | +1.26% |
| Week 3 | $5.01 | $6.54 | $8.54 | +1.90% |
| Week 4 | $4.84 | $6.58 | $8.95 | +2.54% |
| Week 5 | $4.70 | $6.62 | $9.34 | +3.18% |
| Week 6 | $4.57 | $6.67 | $9.71 | +3.83% |
| Week 7 | $4.47 | $6.71 | $10.07 | +4.48% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100, is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer.
LB-100 is also studied in combination with doxorubicin for advanced soft tissue sarcoma in the Phase 1b portion, and with dostarlimab in a phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; a collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc.
was founded in 2005 and is based in Boca Raton, Florida.
Lixte Biotechnology Holdings, Inc. trades under the symbol LIXT in the healthcare sector. The current price is $6.42 and the company has a market capitalization of $79.5M, with a market position ranked at 4319.
The stock is positioned within a broader price trajectory that the forecast maps across multiple years, with near-term neutral tones and longer-term bullish potential. The asset sits amid a known 30-day price range and defined technical levels that inform near-term decision-making.
A major floor 68.7% below — a decisive break under it would weaken the trend.
The nearest floor, 51.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 34.4% above — clearing it would confirm fresh momentum.
Key LIXT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LIXT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.89 | Buy | $5.88 | Buy |
| MA 10 | $5.46 | Buy | $5.55 | Buy |
| MA 20 | $4.87 | Buy | $5.03 | Buy |
| MA 50 | $3.84 | Buy | $4.24 | Buy |
| MA 100 | $3.52 | Buy | $3.88 | Buy |
| MA 200 | $3.97 | Buy | $3.63 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 74.56 | Sell |
| Stoch RSI (14) | 93.91 | Sell |
| CCI (20) | 149.94 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.09 | Buy |
| ROC (12) | 24.42 | Buy |
| Bollinger %B (20,2) | 0.95 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 2.02 | Buy |
| Awesome (5,34) | 1.63 | Buy |
| Ultimate (7,14,28) | 74.21 | Sell |
| Momentum (10) | 1.35 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 6.18 | Buy |
| ADX (14) | 34.14 | Buy |
| ATR (14) | 0.26 | Info |
Technically, the sentiment is BULLISH with an RSI(14) of 70, indicating strong momentum. The stock trades above both the SMA50 at $3.84 and the SMA200 at $3.97, signaling constructive momentum to the upside.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.44 | $6.42 | $10.32 | 0% | Neutral | |
| $5.32 | $7.40 | $11.12 | +15% | Neutral | |
| $5.89 | $8.68 | $13.87 | +35% | Bullish | |
| $6.80 | $10.56 | $17.70 | +65% | Bullish | |
| $7.07 | $11.50 | $20.06 | +79% | Bullish | |
| $10.92 | $18.56 | $33.47 | +189% | Bullish | |
| $12.59 | $22.32 | $41.48 | +248% | Bullish | |
| $10.95 | $20.20 | $38.58 | +215% | Bullish | |
| $11.71 | $22.48 | $44.00 | +250% | Bullish | |
| $11.13 | $22.20 | $44.47 | +246% | Bullish | |
| $20.16 | $44.79 | $98.53 | +598% | Bullish | |
| $54.14 | $120.32 | $276.74 | +17.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.44 | $6.42 | $7.62 | +0.00% |
| June 2026 | $5.37 | $6.44 | $8.00 | +0.31% |
| July 2026 | $5.71 | $6.97 | $8.88 | +8.16% |
| August 2026 | $6.06 | $7.49 | $9.73 | +7.53% |
| September 2026 | $5.90 | $7.37 | $9.72 | -1.62% |
| October 2026 | $5.76 | $7.27 | $9.73 | -1.35% |
| November 2026 | $5.95 | $7.58 | $10.27 | +4.29% |
| December 2026 | $5.86 | $7.53 | $10.32 | -0.65% |
Click any year to see its month-by-month LIXT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The LIXT price prediction for 2026 points to an average of $6.42 (low $2.44, high $10.32) — a potential gain of 0% on today's $6.42. Price action looks broadly range-bound.
In 2027, LIXT is projected to trade between $5.32 and $11.12, averaging $7.40 — a potential gain of +15% from today's $6.42. That is up +15% on the projected 2026 average. A consolidation phase looks the most probable path here.
Lixte Biotechnology Holdings, Inc.'s 2028 outlook centres on $8.68, within a $5.89 to $13.87 range. That is up +17% on the projected 2027 average. That marks a +35% change versus current levels. Momentum favours further upside here.
By 2029, LIXT could reach as high as $17.70, with a base case around $10.56 and support toward $6.80 — roughly +65% from $6.42. Buyers look set to stay in control over this stretch.
Expect LIXT to range from $7.07 to $20.06 through 2030. The $11.50 average target implies a +79% move from current prices. That is up +9% on the projected 2029 average. Momentum favours further upside here.
The LIXT price prediction for 2031 points to an average of $18.56 (low $10.92, high $33.47) — a potential gain of +189% on today's $6.42. Buyers look set to stay in control over this stretch.
In 2032, LIXT is projected to trade between $12.59 and $41.48, averaging $22.32 — a potential gain of +248% from today's $6.42. That is up +20% on the projected 2031 average. Momentum favours further upside here.
Lixte Biotechnology Holdings, Inc.'s 2033 outlook centres on $20.20, within a $10.95 to $38.58 range. That is -9% versus the projected 2032 average. That marks a +215% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, LIXT could reach as high as $44.00, with a base case around $22.48 and support toward $11.71 — roughly +250% from $6.42. Momentum favours further upside here.
Expect LIXT to range from $11.13 to $44.47 through 2035. The $22.20 average target implies a +246% move from current prices. That is -1% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
The LIXT price prediction for 2040 points to an average of $44.79 (low $20.16, high $98.53) — a potential gain of +598% on today's $6.42. Momentum favours further upside here.
In 2050, LIXT is projected to trade between $54.14 and $276.74, averaging $120.32 — a potential gain of +17.7x from today's $6.42. That is up +169% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in LIXT today (≈ 155.76324 LIXT) could be worth
$18,741.62
+$17,741.62 (+1774%) by 2050 · US Dollar
Based on the average projected LIXT price of $120.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LIXTwould be worth at today's price.
$1,000 invested in LIXT on May 27, 2025 (≈ 751.879675 LIXT) would be worth
$4,827.07
+$3,827.07 (+382.7%) today · 4.83× · US Dollar
Based on a LIXT entry price of $1.33 vs. today's $6.42.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.6 | $1,146.43 | +14.6% |
| 1 month ago | $3.8 | $1,689.47 | +68.9% |
| 3 months ago | $2.91 | $2,206.19 | +120.6% |
| 6 months ago | $4.27 | $1,503.51 | +50.4% |
| 1 year ago | $1.33 | $4,827.07 | +382.7% |
| All time (5.0y) ago | $28.4 | $226.06 | -77.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LIXT forecast.
Our base-case forecast reaches $13.00 around 2031.
Implied market cap at $13.00: $160.98M
The multi-year forecast shows a rising trajectory, with 2026 an avg of $6.42 and 2026 max of $10.32 (min $2.44), yielding a neutral outlook for that year. The projection strengthens through 2027–2030, with 2030 an avg of $11.50 and a max of $20.06, yielding a 79.2% ROI; sentiment remains BULLISH. Beyond 2030, the forecast continues higher, with 2040 an avg of $44.79 and a max of $98.53 (ROI 597.7%), and 2050 an avg of $120.32 and a max of $276.74 (ROI 1774.2%).
These figures imply a bullish long-term stance but are estimates, not guarantees, and carry uncertainty and risks.
Tap a question to reveal the answer.
For 2030, the forecast shows an avg price of $11.50 with a min of $7.07, a max of $20.06, and an ROI of 79.2%.
The forecast depicts bullish sentiment from 2028 onward, with rising averages (2028 avg $8.68; 2029 avg $10.56; 2030 avg $11.50) and growing ROI (e.g., 2029 ROI 64.5%, 2030 ROI 79.2%, 2050 ROI 1774.2%), though confidence varies by year and these are estimates.
Yes—the max forecast for 2030 is $20.06, while the avg is $11.50 and the min is $7.07, indicating a potential to reach around $20 in that year under certain conditions.
The 30-day range is $4.38 to $9.41, illustrating near-term volatility around the current price of $6.42.
Current price is $6.42, market cap is $79.5M, and the rank is 4319.
Lixte Biotechnology Holdings, Inc. Community Discussion
0Share your Lixte Biotechnology Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.